预约演示
Charles River inks viral vector production pact for Navega's chronic pain gene therapy
基因疗法并购临床1期细胞疗法
Charles River will help bring NT-Z001 to the clinic by leveraging its off-the-shelf plasmid products, custom plasmid capabilities and adeno-associated virus (AAV) production.
After charting multiple personNT-Z001medicine expansions in recent years, contract manufacturer Charles River Laboratories is back with another gene therapy pact—this time centered on an adeno-associated virus 9 (AAV9) candidate meant to serve as a non-opioid alternative for rare disease patients living with chronic pain.
Charles River on Thursday announced a new accord with epigenetic gene therapy outfit Navega TherCharles River LaboratoriesMO’s Cell and Gene Therapy Accelerator Program.chronic pain
The deal will grant Navega access to Charles River’s contract development and manufacNavega Therapeutics and advisory services to produce the AAV gene therapy candidate NT-Z001 for phase 1 clinical trials, the companies said in a press release.
Navega1 specifically addresses a gain-of-function mutation in tchronic painene, which is linked to inherited ersmall fiber neuropathyiber primary erythromelalgiaronic, debilitating pNavegasorders. Aside from pain tied to rare diseases, Navega figures its gene therapy could eventually address other pain indications, including neuropathic and inflammatory pain.
NT-Z001 River, for its part, will help bring NT-Z001 to the clinic by leveraging its off-the-shelf inherited erythromelalgiaplsmall fiber neuropathy AAV production.pain disorderspainNavegapainneuropathic and inflammatory pain
Over the years, Charles River says it has sigNT-Z001tly enhanced its cell and gene portfolio through a mix of acquisitions, capacity expansions and manufacturing platform launches, including eXpDNA for plasmids, nAAVigation for AAV and Lentivation for lentiviral vectors.
Back in November 2022, the company debuted the expansion of its cell therapy manufacturing facility in Memphis, Tennessee. The plant reveal came just weeks after the CDMO opened a separate plasmid production facility in the U.K. Under the expansion, Charles River added nine processing suites to its 16 clean rooms at the Memphis site.
The additions were designed to handle high-volume production—plus options for dual production lines—for late-stage clinical and commercial cell therapies, the company said at the time.
Charles River also recently acquired a site in Rockville, Maryland, through its $350-million buyout of gene therapy CDMO Vigene Biosciences back in 2021. The site largely helps with the production of viral vectors, which have experienced supply constraints among advanced cell and gene therapies for several years.
Elsewhere on the personalized medicines front, Charles River last year linked up with South Korea’s Rznomics to deveCDMOaVigene Biosciences vectors for its partner’s experimental liver cancer gene therapy RZ-001. RZ-001 marks the first ribozyme-based RNA reprogramming approach to receive FDA authorization for evaluation in humans, the companies said last January.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
靶点
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。